XEME is actively seeking to leverage its Aggregon® platform and patents with collaborations and licensing agreements in the area of therapeutic cancer vaccines based on cells and/or tumor proteins. In this respect, XEME’s products are particularly suited for joint collaborations with companies utilizing strategies based on dendritic cells or tumor neo-antigens. XEME is also seeking to enhance the efficacy of its vaccines by entering into a joint clinical development partnership with pharmaceutical companies that market checkpoint inhibitors.
At the research level, XEME is seeking collaborations with industrial and academic partners to expand its products in the areas of solid tumor ,“in situ” vaccination, and autoimmunity.
For interested partners, XEME is also in the position to contract-manufacture gram quantities of IL-2 (soluble form) under cGMP for R&D and clinical research.
Invest in XEME
XEME is offering a Series A Preferred Stock will be sold in a private placement exempt from registration pursuant to Section 4(a)(2) and/or Rule 506(b) of the Securities Act of 1933, as amended (the “Securities Act”), to only ‘accredited investors’ as such term is defined in the Securities Act.
The capital raised will be used to complete ongoing trials in hematological malignancies, initiate new pre-clinical and clinical studies in solid tumor indications and strengthen intellectual property portfolio.